Eisai Inc., of Woodcliff Lake, N.J., the U.S. subsidiary of Tokyo-based Eisai Co. Ltd., said data from the phase III REFLECT trial testing Lenvima (lenvatinib mesylate) in 954 patients with unresectable hepatocellular carcinoma were published in The Lancet. Lenvima produced a median overall survival of 13.6 months compared to 12.3 months for Nexavar (sorafenib, Bayer AG).